0728 GMT - Samsung Biologics is likely to benefit from rising contract development and manufacturing organization penetration, Nomura's analyst Cindy Park says in a research report. Nomura's view is partly based on strong global demand for large-scale contract manufacturing organizations, as pharmaceutical firms are increasingly transitioning into CDMOs to minimize risks related to high capex and uncertainties on drug approvals. CDMO penetration in global bio-pharmaceutical industry for mammalian cells will likely rise to 45% by 2030 from estimated 35% this year, with the South Korean contract development and manufacturing organization likely to be a key beneficiary. Nomura assumes coverage of the stock with a buy rating and a target price of KRW1,400,000.00. It previously held a neutral rating and a target price of KRW840,000.00. Shares closed 1.7% higher at KRW1,069,000.00. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
March 17, 2025 03:28 ET (07:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.